ES2009133B3 - Procedimiento de preparacion de (-)-benzhidrilsulfinilacetamida. - Google Patents

Procedimiento de preparacion de (-)-benzhidrilsulfinilacetamida.

Info

Publication number
ES2009133B3
ES2009133B3 ES87400114T ES87400114T ES2009133B3 ES 2009133 B3 ES2009133 B3 ES 2009133B3 ES 87400114 T ES87400114 T ES 87400114T ES 87400114 T ES87400114 T ES 87400114T ES 2009133 B3 ES2009133 B3 ES 2009133B3
Authority
ES
Spain
Prior art keywords
benzhidrilsulfinilacetamida
vis
preparation procedure
derivative
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES87400114T
Other languages
English (en)
Inventor
Louis Lafon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon France SAS
Original Assignee
Laboratoire L Lafon SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire L Lafon SA filed Critical Laboratoire L Lafon SA
Application granted granted Critical
Publication of ES2009133B3 publication Critical patent/ES2009133B3/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Abstract

LA PRESENTE INVENCION TRATA DEL DERIVADO LEVOGIRO DE BENZHIDRILSULFINILACETAMIDA. ESTE DERIVADO ES UTILIZADO EN TERAPEUTICA COMO MEDIO ESTIMULANTE DEL SNC VIS-A-VIS DE LA ENFERMEDAD DE ALZHEIMER Y COMO MEDIO DESPERTADOR VIS-A-VIS DEL HIPERSOMMIO.
ES87400114T 1986-01-31 1987-01-19 Procedimiento de preparacion de (-)-benzhidrilsulfinilacetamida. Expired ES2009133B3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8601337A FR2593809B1 (fr) 1986-01-31 1986-01-31 Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique

Publications (1)

Publication Number Publication Date
ES2009133B3 true ES2009133B3 (es) 1989-09-01

Family

ID=9331665

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87400114T Expired ES2009133B3 (es) 1986-01-31 1987-01-19 Procedimiento de preparacion de (-)-benzhidrilsulfinilacetamida.

Country Status (10)

Country Link
US (1) US4927855A (es)
EP (1) EP0233106B1 (es)
JP (1) JPH06102623B2 (es)
CA (1) CA1274543A (es)
DE (1) DE3760201D1 (es)
DK (1) DK165594C (es)
ES (1) ES2009133B3 (es)
FR (1) FR2593809B1 (es)
GR (1) GR3000128T3 (es)
IE (1) IE59832B1 (es)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) * 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2697162B1 (fr) * 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
FR2708201B1 (fr) * 1993-06-30 1995-10-20 Lafon Labor Utilisation de dérivés d'acétamide pour la fabrication de médicaments.
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
US6346548B1 (en) 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
FR2804322B1 (fr) * 2000-01-31 2002-04-19 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies
US6670358B2 (en) * 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides
US6492396B2 (en) * 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
EP2168946A1 (en) * 2000-07-27 2010-03-31 Teva Pharmaceutical Industries Ltd Crystalline form of modafinil, and methods of preparing the crystalline form
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6489363B2 (en) 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
IL155322A0 (en) * 2000-10-11 2003-11-23 Cephalon Inc Compositions comprising modafinil compounds
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7704975B2 (en) * 2000-12-19 2010-04-27 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7297346B2 (en) * 2001-05-25 2007-11-20 Cephalon Inc. Pharmaceutical formulations of modafinil
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
AU2003213719A1 (en) * 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
ITMI20020991A1 (it) * 2002-05-10 2003-11-10 Dinamite Dipharma S P A In For Procedimento per la sintesi del modafinil
US6875893B2 (en) * 2002-05-23 2005-04-05 Cephalon, Inc. Preparations of a sulfinyl acetamide
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
FR2849029B1 (fr) * 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
WO2004075827A2 (en) * 2003-01-31 2004-09-10 Alembic Limited Process for the preparation of 2-[(diphenylmethyl) thio] acetamide
US7244865B2 (en) 2003-02-24 2007-07-17 Mallinckrodt Inc. Process for preparing benzhydrylthioacetamide
ES2487415T3 (es) * 2003-03-17 2014-08-20 Neurohealing Pharmaceuticals, Inc. Tratamiento dopaminérgico de alta potencia de deficiencias neurológicas asociadas con lesiones cerebrales
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
AR045314A1 (es) * 2003-05-13 2005-10-26 Cephalon Inc Composiciones farmaceuticas de analepticos y antidepresivos
US20040229941A1 (en) * 2003-05-13 2004-11-18 Cephalon, Inc. Analeptic and antidepressant combinations
AR045423A1 (es) * 2003-05-13 2005-10-26 Cephalon Inc Combinaciones de analiticos y antidepresivos
US20040242698A1 (en) * 2003-05-13 2004-12-02 Cephalon Inc. Analeptic and antidepressant combinations
ATE442352T1 (de) 2003-05-16 2009-09-15 Cephalon France Verfahren zur herstellung von modafinil
ITMI20031298A1 (it) * 2003-06-26 2004-12-27 Erregierre Spa Processo di preparazione di modafinil forma polimorfa(i).
AU2004270238B2 (en) * 2003-09-04 2010-07-29 Cephalon, Inc. Modafinil compositions
EP1670753A4 (en) * 2003-09-04 2008-01-02 Cephalon Inc MODAFINIL COMPOSITIONS
US7566805B2 (en) * 2003-09-04 2009-07-28 Cephalon, Inc. Modafinil compositions
WO2005046854A2 (en) * 2003-09-12 2005-05-26 Sun Pharmaceutical Industries Limited A process for the preparation of diphenylmethylsulfinyl derivatives
EP1516869A1 (en) * 2003-09-19 2005-03-23 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
EP2292213A1 (en) * 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
US20090018202A1 (en) 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
AU2005212229B2 (en) * 2004-02-06 2011-06-09 Cephalon, Inc. Modafinil compositions
CN1980888B (zh) * 2004-02-06 2011-04-13 赛福伦公司 莫达芬尼组合物
US7449481B2 (en) * 2004-04-13 2008-11-11 Cephalon, Inc. Thio-substituted biaryl-methanesulfinyl derivatives
EP1586560A1 (en) * 2004-04-13 2005-10-19 Cephalon, Inc. Thio-substituted arylmethanesulfinyl derivatives
WO2005099822A2 (en) * 2004-04-13 2005-10-27 Cephalon, Inc. Reduction of drug / drug interactions with modafinil
US7297817B2 (en) * 2004-04-13 2007-11-20 Cephalon France Thio-substituted arylmethanesulfinyl derivatives
US7314875B2 (en) * 2004-04-13 2008-01-01 Cephalon, Inc. Tricyclic aromatic and bis-phenyl sulfinyl derivatives
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
EP1634861A1 (en) * 2004-09-13 2006-03-15 Cephalon, Inc. Methods for the separation of modafinil
US20060086667A1 (en) * 2004-09-13 2006-04-27 Cephalon, Inc., U.S. Corporation Methods for the separation of enantiomeric sulfinylacetamides
EP1702915A1 (en) * 2005-03-14 2006-09-20 Cephalon France Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation
CA2614777C (en) * 2005-07-21 2012-04-17 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
ES2388876T3 (es) * 2005-07-29 2012-10-19 Vanda Pharmaceuticals Inc. Uso de [2-(2-metilimidazol-1-il)metil]piridina para tratamiento de trastornos del sueño
ITMI20051971A1 (it) 2005-10-18 2007-04-19 Dipharma Spa Procedimento per la preparazione di - modafinil
WO2007070238A2 (en) * 2005-12-09 2007-06-21 Mallinckrodt Inc. Processes for the preparation of modafinil and analogs thereof
EP1986994A2 (en) * 2006-02-21 2008-11-05 Teva Pharmaceutical Industries Ltd Novel crystalline forms of armodafinil and preparation thereof
EP1954652A2 (en) * 2006-03-01 2008-08-13 Teva Pharmaceutical Industries Ltd An improved process for the preparation of armodafinil
BRPI0714173A2 (pt) * 2006-07-12 2012-12-25 Elan Pharma Int Ltd composiÇço nanoparticulada estÁvel,mÉtodos para preparar a composiÇço, para prevenir e/ou tratar estados de doenÇas, sintomas, sÍndromes e condiÇÕes do sistema nervoso central, para melhorar ou manter a biodisponibilidade de modafinil, e para tratar distérbio com base neurolàgica, composiÇço farmacÊutica, e forma de dosagem
EP2056811B8 (en) * 2006-08-14 2018-03-21 Neurohealing Pharmaceuticals, Inc. Modafinil-based treatment for premature ejaculation
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
WO2008070143A1 (en) * 2006-12-06 2008-06-12 Teva Pharmaceutical Industries Ltd. Processes for preparing armodafinil intermediate
WO2008077127A2 (en) * 2006-12-19 2008-06-26 Lavin Thomas N Use of modafinil to treat restless leg syndrome
US9289403B2 (en) * 2007-03-09 2016-03-22 The Board of Trustees of the University of Arizona Use of modafinil to treat spasticity
EP2155664A2 (en) * 2007-06-04 2010-02-24 Generics Ýuk¨Limited Novel process
US7960586B2 (en) * 2007-08-16 2011-06-14 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
US20090082462A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched armodafinil
EP1911739A3 (en) * 2007-11-05 2008-09-17 Dipharma Francis S.r.l. Crystalline form of (S)-2-phenylethylammonium (R)-diphenyl-methanesulphinyl-acetate
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US20100036164A1 (en) * 2008-08-06 2010-02-11 Srinivas Areveli Preparation of armodafinil form i
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
DK2649187T3 (da) 2010-12-08 2018-01-29 Codexis Inc Biokatalysatorer og fremgangsmåder til syntesen af armodafinil
FR2970711B1 (fr) * 2011-01-20 2016-03-04 Hopitaux Paris Assist Publique La lauflumide et ses enantiomeres, preparation et utilisations therapeutiques
CN103058900B (zh) * 2012-12-14 2014-11-26 重庆康乐制药有限公司 一种r-二苯甲基亚硫酰乙酸的制备方法
CA2903746C (en) 2013-03-08 2022-08-23 Amy Hauck Newman Potent and selective inhibitors of monoamine transporters; method of making; and use thereof
CN104341327A (zh) * 2013-08-08 2015-02-11 中国人民解放军63975部队 多卤素取代2-(二苯甲基亚硫酰基)乙酰胺类化合物及其立体异构体
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement
WO2019094856A1 (en) 2017-11-13 2019-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Atypical inhibitors of monoamine transporters; method of making; and use thereof
KR102126389B1 (ko) 2018-09-14 2020-06-25 셀라이온바이오메드 주식회사 벤즈히드릴티오 아세트아미드 화합물을 유효성분으로 포함하는 간 질환의 예방 또는 치료용 조성물
KR102277739B1 (ko) 2019-12-11 2021-07-15 셀라이온바이오메드 주식회사 벤즈히드릴 티오 아세트아미드 화합물을 유효성분으로 포함하는 섬유화 질환의 치료용 조성물
CN115835862A (zh) * 2020-07-10 2023-03-21 广州新创忆药物临床研究有限公司 治疗阿尔茨海默病的组合及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2528038B2 (fr) * 1982-06-04 1985-08-09 Lafon Labor Derives de benzhydrylsulfinylacetamide et leur utilisation en therapeutique

Also Published As

Publication number Publication date
DK49687D0 (da) 1987-01-30
FR2593809B1 (fr) 1988-07-22
GR3000128T3 (en) 1990-11-29
US4927855A (en) 1990-05-22
DK49687A (da) 1987-08-01
CA1274543A (fr) 1990-09-25
FR2593809A1 (fr) 1987-08-07
EP0233106A1 (fr) 1987-08-19
JPH06102623B2 (ja) 1994-12-14
JPS62190160A (ja) 1987-08-20
EP0233106B1 (fr) 1989-05-31
DK165594B (da) 1992-12-21
DK165594C (da) 1993-05-03
DE3760201D1 (en) 1989-07-06
IE870240L (en) 1987-07-31
IE59832B1 (en) 1994-04-06

Similar Documents

Publication Publication Date Title
ES2009133B3 (es) Procedimiento de preparacion de (-)-benzhidrilsulfinilacetamida.
LU90710I2 (fr) Galanthamine ou ses sels d'addition acides
NO169121C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 9-amino-1,2,3,4-tetrahydroakridin-1-oler
DK549189A (da) Galanthamin-analoge samt anvendelse af disse til fremstilling af laegemidler til behandling af alzheimer's syge
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE69124293T2 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
FI941245A (fi) Menetelmä 2'-deoksiguanosiinin asyylijohdannaisten valmistamiseksi
IL86423A0 (en) Pharmaceutical compositions for the treatment of alzheimer's disease
ES2059501T5 (es) Aminoacidos utiles en trastornos hepaticos.
ZM3087A1 (en) Treatment of diseases caused by retroviruses
DE3583220D1 (de) Verwendung von dipeptidderivaten fuer die herstellung von arzneimitteln zur behandlung von an amyotropher lateralsklerose erkrankten.
ES2054687T3 (es) Utilizacion de medetomidina en la fabricacion de un medicamento.
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
ATE142503T1 (de) Arzneimittelzubereitung bei der behandlung von tonsillitis
IT1222099B (it) Poliesteri del 4,4' diidrossibicicloesile
DE68928763D1 (de) Verfahren zur Herstellung von isolierten vertikalbipolaren und JFET-Transistoren und entsprechender IC
LV10391A (lv) Alkilfosforskabes savienojumu izmantosana psoriazes tipa slimibu arstesanai
DE59010504D1 (de) Typisierung humaner Rhinoviren
DE68915793D1 (de) Verwendung von 6RF zur Diagnose von M. Alzheimer.
SE8802323L (sv) 8alfa-acylaminoergolin, dess framstaellning samt farmaceutiska kompositioner innehaallande detsamma
FR2628322B1 (fr) Nouvelles utilisations therapeutiques de l'acide 4-(3-phosphono-2-propenyl)-piperazine-2-carboxylique
IT8601223A0 (it) Strumento indicatore del grado di abbronzatura dell'epidermide.
ATE66373T1 (de) Verwendung des 2-amino-6-allyl-5,6,7,8-tetrahydro-4h-thiazolo( ,5-d>azepins zur herstellung eines zur behandlung der parkinsonschen erkrankung bzw. des parkinsonismus geeigneten arzneimittels.
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.